Product Description
Calcium chloride is an ionic compound of calcium and chlorine. It is highly soluble in water and it is deliquescent. It is a salt that is solid at room temperature, and it behaves as a typical ionic halide. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Calcium-dichloride)
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Denmark | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Lebanon | Malaysia | Malta | Mexico | New Zealand | Norway | Pakistan | Philippines | Poland | Russia | Saudi Arabia | Serbia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Julie Gehl
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description

Countries in Clinic: Italy, United States
Active Clinical Trial Count: 5
Highest Development Phases
Phase 3: Heart Failure
Phase 2: Acute Kidney Injury|Muscle Weakness|Skin Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CQ-001-19 | P3 |
Recruiting |
Heart Failure |
2027-04-01 |
|
SeND Home | P2 |
Recruiting |
Muscle Weakness |
2025-06-30 |
|
BiPhox-Trial | P2 |
Active, not recruiting |
Acute Kidney Injury |
2023-06-10 |
|
2019-004314-34 | P2 |
Active, not recruiting |
Unknown |
2022-06-04 |